{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T21:46:35Z","timestamp":1792100795877,"version":"4.4.0"},"reference-count":22,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T00:00:00Z","timestamp":1789862400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca PLC","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100022274","name":"Daiichi Sankyo Europe GmbH","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100022274","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thebreastonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Breast"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.breast.2026.104933","type":"journal-article","created":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T14:28:31Z","timestamp":1790519311000},"page":"104933","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Chemotherapy outcomes in human epidermal growth factor receptor 2-low, hormone receptor-positive metastatic breast cancer: Insights from the French multicenter ESME database"],"prefix":"10.1016","volume":"90","author":[{"given":"William","family":"Jacot","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0110-2415","authenticated-orcid":false,"given":"Pauline","family":"Macouillard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suyuan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8754-0530","authenticated-orcid":false,"given":"Danalyn","family":"Byng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9435-7737","authenticated-orcid":false,"given":"Shannon","family":"Hunter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Massard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5273-0561","authenticated-orcid":false,"given":"Jean-S\u00e9bastien","family":"Frenel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6429-7419","authenticated-orcid":false,"given":"David","family":"P\u00e9rol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0881-9371","authenticated-orcid":false,"given":"Etienne","family":"Brain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Audrey","family":"Mailliez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Bachelot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5269-1251","authenticated-orcid":false,"given":"Monica","family":"Arnedos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5100-9425","authenticated-orcid":false,"given":"Lise","family":"Bosquet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8094-4738","authenticated-orcid":false,"given":"V\u00e9ronique","family":"Di\u00e9ras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.breast.2026.104933_bib1","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.clbc.2021.10.007","article-title":"The place of chemotherapy in the evolving treatment landscape for patients with HR-positive\/HER2-negative MBC","volume":"22","author":"Twelves","year":"2022","journal-title":"Clin Breast Cancer"},{"key":"10.1016\/j.breast.2026.104933_bib2","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1016\/j.annonc.2021.09.019","article-title":"ESMO clinical practice guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer","volume":"32","author":"Gennari","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.breast.2026.104933_bib3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41523-020-00208-2","article-title":"Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer","volume":"7","author":"Schettini","year":"2021","journal-title":"NPJ Breast Cancer"},{"key":"10.1016\/j.breast.2026.104933_bib4","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.annonc.2023.05.008","article-title":"ESMO expert consensus statements (ECS) on the definition, diagnosis, and management of HER2-low breast cancer","volume":"34","author":"Tarantino","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.breast.2026.104933_bib5","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.semcancer.2020.02.016","article-title":"Evolving concepts in HER2 evaluation in breast cancer: heterogeneity, HER2-low carcinomas and beyond","volume":"72","author":"Marchi\u00f2","year":"2021","journal-title":"Semin Cancer Biol"},{"key":"10.1016\/j.breast.2026.104933_bib6","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2203690","article-title":"Trastuzumab deruxtecan in previously treated HER2-Low advanced breast cancer","volume":"387","author":"Modi","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.breast.2026.104933_bib7","doi-asserted-by":"crossref","DOI":"10.3390\/cancers16040800","article-title":"Next-generation HER2-targeted antibody-drug conjugates in breast cancer","volume":"16","author":"Zimmerman","year":"2024","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.breast.2026.104933_bib8","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.1056\/NEJMoa2407086","article-title":"Trastuzumab deruxtecan after endocrine therapy in metastatic breast cancer","volume":"391","author":"Bardia","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.breast.2026.104933_bib10","series-title":"ESMO metastatic breast cancer living guidelines","author":"Gennari","year":"2025"},{"key":"10.1016\/j.breast.2026.104933_bib11","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2018-023568","article-title":"The ongoing French metastatic breast cancer (MBC) cohort: the example-based methodology of the epidemiological strategy and medical economics (ESME)","volume":"9","author":"P\u00e9rol","year":"2019","journal-title":"BMJ Open"},{"key":"10.1016\/j.breast.2026.104933_bib26","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.56170","article-title":"Regulatory approval, reimbursement, and clinical use of cyclin-dependent kinase 4\/6 inhibitors in metastatic breast cancer in the Netherlands","volume":"6","author":"Luyendijk","year":"2023","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.breast.2026.104933_bib15","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2025-104228","article-title":"GABRINOX-2 protocol: a French, prospective, multicentre, randomised phase II trial evaluating gemcitabine\/nab-paclitaxel followed by FOLFIRINOX versus FOLFIRINOX alone as first-line treatment for metastatic pancreatic cancer","volume":"15","author":"Portales","year":"2025","journal-title":"BMJ Open"},{"key":"10.1016\/j.breast.2026.104933_bib16","doi-asserted-by":"crossref","first-page":"4584","DOI":"10.1038\/s41598-025-88394-6","article-title":"Clinical characteristics, metastasis patterns, and treatment outcomes of HER2-low breast cancer","volume":"15","author":"Lacruz","year":"2025","journal-title":"Sci Rep"},{"key":"10.1016\/j.breast.2026.104933_bib17","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1111\/1759-7714.15221","article-title":"Prognostic value and relapse pattern of HER2-low in hormone receptor-positive breast cancer","volume":"15","author":"Wei","year":"2024","journal-title":"Thorac Cancer"},{"key":"10.1016\/j.breast.2026.104933_bib18","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.breast.2022.11.003","article-title":"Real-world data of HER2-low metastatic breast cancer: a population based cohort study","volume":"66","author":"Holthuis","year":"2022","journal-title":"Breast"},{"key":"10.1016\/j.breast.2026.104933_bib19","doi-asserted-by":"crossref","DOI":"10.1177\/17588359251378863","article-title":"Real-world analysis of HER2-ultralow in HR+\/HER2- metastatic breast cancer: prevalence and first-line chemotherapy outcomes","volume":"17","author":"Mathiot","year":"2025","journal-title":"Ther Adv Med Oncol"},{"key":"10.1016\/j.breast.2026.104933_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.101931","volume":"59","author":"Lambertini","year":"2023","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.breast.2026.104933_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2024.115113","article-title":"The journey of patients affected by metastatic hormone receptor-positive\/HER2-negative breast cancer from CDK 4\/6 inhibitors to second-line treatment: a real-world analysis of 701 patients enrolled in the GIM14\/BIOMETA study","volume":"213","author":"Molinelli","year":"2024","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.breast.2026.104933_bib22","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.breast.2020.10.005","article-title":"Eligibility of real-world patients with metastatic breast cancer for clinical trials","volume":"54","author":"Batra","year":"2020","journal-title":"Breast"},{"key":"10.1016\/j.breast.2026.104933_bib23","article-title":"Second-line therapies after CDK4\/6 inhibitor failure in HR-positive\/HER2-negative metastatic breast cancer patients: real-world data from the HERMIONE-13 study","volume":"11","author":"Cazzaniga","year":"2026","journal-title":"ESMO Real World Data Digit Oncol"},{"key":"10.1016\/j.breast.2026.104933_bib24","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1007\/s10549-020-05837-6","article-title":"The efficacy of first-line chemotherapy in endocrine-resistant hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer","volume":"183","author":"Chainitikun","year":"2020","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.breast.2026.104933_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2024.103691","article-title":"Real-world treatment patterns and outcomes in patients with HR+\/HER2- metastatic breast cancer treated with chemotherapy in the United States","volume":"9","author":"Tolaney","year":"2024","journal-title":"ESMO Open"}],"container-title":["The Breast"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960977626002432?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960977626002432?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T21:38:51Z","timestamp":1792100331000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960977626002432"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":22,"alternative-id":["S0960977626002432"],"URL":"https:\/\/doi.org\/10.1016\/j.breast.2026.104933","relation":{},"ISSN":["0960-9776"],"issn-type":[{"value":"0960-9776","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Chemotherapy outcomes in human epidermal growth factor receptor 2-low, hormone receptor-positive metastatic breast cancer: Insights from the French multicenter ESME database","name":"articletitle","label":"Article Title"},{"value":"The Breast","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.breast.2026.104933","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Daiichi Sankyo Europe GmbH. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"104933"}}